Table 2.
Risk factors for development of DLR among non-Hodgkin’s lymphoma patients with HBV reactivation during chemotherapy
|
DLR (-) |
DLR (+) |
|||||
| Total | n | % | n | % | P | |
| Number of patients | 31 | 16 | 51.6 | 15 | 48.4 | |
| Age (yr) | ||||||
| ≤45 | 11 | 4 | 36.4 | 7 | 65.6 | 0.2734 |
| >45 | 20 | 12 | 60 | 8 | 40 | |
| Sex | ||||||
| Female | 14 | 7 | 50 | 7 | 50 | 1 |
| Male | 17 | 9 | 52.9 | 8 | 47.1 | |
| GPT>10X | ||||||
| Yes | 19 | 8 | 42.1 | 11 | 57.9 | 0.2734 |
| No | 12 | 8 | 66.7 | 4 | 33.4 | |
| HBeAg | ||||||
| Present | 29 | 16 | 55.2 | 13 | 44.8 | 0.2258 |
| Absent | 2 | 0 | 0 | 2 | 100 | |
| HBV genotype C | ||||||
| No | 21 | 13 | 61.9 | 8 | 38.1 | 0.0768 |
| Yes | 7 | 1 | 14.3 | 6 | 85.7 | |
| Unknown or mixed type | 3 | 2 | 66.7 | 1 | 33.3 | |
| Total bilirubin >5 | ||||||
| Yes | 5 | 1 | 20 | 4 | 80 | 0.1719 |
| No | 26 | 15 | 57.7 | 11 | 42.3 | |
| Peak HBV DNA >100X | ||||||
| Yes | 18 | 9 | 50 | 9 | 50 | 1 |
| No | 13 | 7 | 53.8 | 6 | 46.2 | |
| Patterns of reactivation | ||||||
| Transient | 16 | 10 | 62.5 | 6 | 37.5 | 0.508 |
| Protracted/resolved | 5 | 3 | 60 | 2 | 40 | |
| Protracted/unresolved | 5 | 1 | 20 | 4 | 80 | |
| Multiple reactivation | 3 | 1 | 33.3 | 2 | 66.7 | |
| Unknown | 2 | 1 | 50 | 1 | 50 | |